Impact of fluconazole administration on outcomes in critically ill patients

Annals of Pharmacotherapy

Volumn 38, Issue 10, 2004, Pages 1588-1592

  Garrelts, James C ^a   Schroeder, Todd R ^a   Harrison, Paul B ^a  

^a WESLEY MEDICAL CENTER   (United States)

Author keywords

Fluconazole; Outcomes; Trauma

Indexed keywords

AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; FLUCONAZOLE; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UREIDOPENICILLIN DERIVATIVE;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; CANDIDA; CANDIDIASIS; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; CRITICAL ILLNESS; FEMALE; FUNGUS CULTURE; HOSPITAL DISCHARGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURGICAL INJURY;

ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CASE-CONTROL STUDIES; CRITICAL ILLNESS; FEMALE; FLUCONAZOLE; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; PRACTICE GUIDELINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 4644289442     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D441     Document Type: Article

References (13)

1. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995;20:1526-30.
2. Vincent JL, Anaissie E, Bruining H, Demajo W, El-Ebiary M, Haber J, et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998;24: 206-16.
3. Edwards JE, Bodey GP, Bowden RA, Bucher T, de Pauw BE, Filler SG, et al. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis 1997;25:43-59.
4. Wey SB, Motomi M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-5.
5. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30:662-78.
6. Pelz RK, Hendrix CW, Swoboda SM, Diener-West M, Merz WG, Hammond J, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001;233:542-8.
7. Rocco TR, Reinert SE, Simms HH. Effects of fluconazole administration in critically ill patients. Analysis of bacterial and fungal resistance. Arch Surg 2000;135:60-5.
8. Safran DB, Dawson E. The effect of empiric and prophylactic treatment with fluconazole on yeast isolates in a surgical trauma intensive care unit. Arch Surg 1997;132:1184-9.
9. Berrouane YF, Herwaldt LA, Pfaller MA. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J Clin Microbiol 1999;37:531-7.
10. Gleason TG, May AK, Caparelli D, Farr BM, Sawyer RG. Emerging evidence of selection of fluconazole tolerant fungi in surgical intensive care units. Arch Surg 1997;132:1197-202.
11. Raffalli J, Falvo C, Seiter K, Arcilla S, Quisumbing E, Chandy D, et al. Risk factors for non-albican's Candida bloodstream infections in a university hospital (abstract J-25). Intersci Conf Antimicrob Agents Chemother 1998;38:458.
12. Snydman DR. Shifting patterns in the epidemiology of nosocomial Candida infections. Chest 2003;123(5 suppl):500S-3S.
13. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994;220:51-8.